Search Results

Histogen Inc., a drug development company for treatment of bacterial skin infections, announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders.

Histogen Inc., announced that its special meeting of stockholders has been adjourned to Thursday, January 4, 2024 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission on October 18, 2023.

Histogen Inc. announced that its special meeting of stockholders has been adjourned to Thursday, December 14, 2023 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission on October 18, 2023.

Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including any proceeds from the potential sale of any pipeline assets.

The companies have announced the impending closures of their respective businesses. Histogen will lay off most of its employees by the end of September. Fresh Tracks will do so by early October.

Histogen Inc. reported financial results for the first quarter ended March 31, 2023, and provided an update on its pipeline and other corporate developments.

Histogen Inc. (HSTO) today announced that the company has signed an exclusive license agreement with Johns Hopkins University.

Histogen Inc. announced the online publication of an abstract describing a preclinical study showing that emricasan has therapeutic effect against bacterial skin infections.

Histogen Inc. reported financial results for the year ended December 31, 2022, and provided an update on its pipeline and other corporate developments.

Histogen Inc. (NASDAQ: HSTO) today announced that the US Patent and Trademark Office (USPTO) has issued US Patent No. 11,579,703 titled “Caspase Inhibitors and Methods of Use Thereof.”